CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that the KARDIA-2 Phase 2 study of zilebesiran, an ...
Hypertension — or high blood pressure — affects about 120 million adults in the U.S. and can lead to heart disease, stroke and chronic kidney disease. There is also a higher prevalence of hypertension ...
Ace Therapeutics announced custom animal models of hypertension, designed to help understand hypertension pathogenesis ...
Despite the availability of effective antihypertensive therapies, global blood pressure control rates remain unacceptably low. Contributing factors, such as low treatment adherence, therapeutic ...
Baxdrostat 2mg lowered systolic blood pressure by 15.7 mmHg (9.8 mmHg placebo-adjusted) from baseline, and was generally well tolerated with no unanticipated safety findings Full results presented at ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced positive results from the KARDIA-2 Phase 2 study evaluating the ...
About 10% of people with hypertension have normal blood pressure readings at the doctor's office. Now researchers at the ...
Pulmovant, a clinical-stage biotechnology company committed to transforming the lives of patients with pulmonary diseases, and a Roivant (Nasdaq: ROIV) company, today announced that it has completed ...
Please provide your email address to receive an email when new articles are posted on . LONDON — Noninvasive testing may predict clinically significant portal hypertension and other outcomes in ...
The Peterson Health Technology Institute, an independent evaluator of digital health technologies, released a report on hypertension solutions Monday that put a crater in the remote monitoring ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results